N

National Allergy and Asthma Research LLC | North Charleston, SC

Research site

(Unclaimed)

Location

7555 Northside Drive, North Charleston, South Carolina, United States of America

Site insights

Top conditions

Top treatments

Dupilumab

OPN-375

Symbicort®

Rocatinlimab

CDX-0159

Bradanicline

BMX-010

EP262

CNP-201

DUPIXENT®

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 19 total trials

Locations recently updated

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...

Enrolling

Atopic Dermatitis

Drug: Rocatinlimab

Drug: Placebo

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial (DISCOVER)

The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a...

Active, not recruiting

Moderate-to-Severe Atopic Dermatitis

Atopic Eczema

Other: Topical emollient (moisturizer)

Drug: dupilumab

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria (CALM-CIndU)

This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and...

Active, not recruiting

Chronic Inducible Urticaria

Drug: Oral EP262

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria (CALM-CSU)

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urtica...

Enrolling

Chronic Spontaneous Urticaria

Drug: Placebo

Drug: Oral EP262